08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
In an effort to provide additional guidance to employers navigating the new Component 2 pay data fil...
Read More >
The COVID-19 pandemic has resulted in significant challenges and opportunities for private equity fi...
Read More >
Last week, I covered some of the basics to think about as the coronavirus continues to spread. Jon H...
Read More >
1. The National Labor Relations Board (NLRB) has clarified its standard for evaluating the legality ...
Read More >
National and international manufacturing companies continue to open new manufacturing facilities, an...
Read More >
In a highly unfavorable peer review decision, Leadbitter v. Keystone Anesthesia v. Petraglia, entere...
Read More >